Industry News
Excerpt from the Press Release: SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, an investigational SHP2 inhibitor,…
Read More
– Findings from the Phase 1 dose escalation portion of the EXACT trial of XC001 in refractory angina provided the dose selection and safety justification for the recently completed Phase 1/2 study -XC001 is a one-time gene therapy candidate designed to reduce ischemic burden by creating new blood vessels in the heart through the local…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patients have been dosed in a Phase 2 dose-expansion clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Aug. 3, 2023 /PRNewswire/ — Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases is pleased to announce the initiation of enrollment into the Ph2a clinical trial of PER-001 intravitreal implant in Diabetic Retinopathy. The Phase 2a trial is a patient masked, randomized, sham-controlled…
Read More
Excerpt from the Press Release: PLEASANTON, Calif., July 26, 2023 /PRNewswire/ — Noctrix Health, Inc. announced a double feature in the renowned peer-reviewed journal, Sleep, showcasing the outcomes of two major clinical trials that assessed TOMAC therapy for the treatment of RLS. The two papers feature the results from the RESTFUL study (NCT04874155), a multi-center,…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the first patient has been enrolled in the National Institutes of Health-sponsored Phase 1/2…
Read More
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety profile Biologics License Application currently under review by U.S. FDA; PDUFA goal date of January 3, 2024 Excerpt from the Press Release: WALTHAM, Mass., July…
Read More
Excerpt from the Press Release: HANGZHOU, China and SAN FRANCISCO, July 11, 2023 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in…
Read More
3Daughters aims to uniquely address and fill major gaps in Women’s Health Assembles experienced Women’s Health team and World Class SAB to advance development of novel long-acting reversible contraception technology Excerpt from the Press Release: MANSFIELD, Mass., July 13, 2023 (GLOBE NEWSWIRE) — 3Daughters, an emerging clinical development company fueling evolutionary healthcare for women, announces…
Read More
Using Medical Images in YourClinical Trial? Keep ThemWorking for You Long after Your Trial Concludes
Medical images play a pivotal role in many clinical trials today. Medical images are assets of tremendous value, yet much of that value remains untapped post trial. Why? Because Sponsors and CROs have not had the software and infrastructure necessary to aggregate and store images, or make them available. With the Fujifilm TeraMedica VNA –…
Read More